These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22275160)

  • 1. Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
    Fava A; Wung PK; Wigley FM; Hummers LK; Daya NR; Ghazarian SR; Boin F
    Arthritis Care Res (Hoboken); 2012 Jun; 64(6):925-9. PubMed ID: 22275160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study.
    Wise RA; Wigley FM; White B; Leatherman G; Zhong J; Krasa H; Kambayashi J; Orlandi C; Czerwiec FS
    Arthritis Rheum; 2004 Dec; 50(12):3994-4001. PubMed ID: 15593189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, randomized, placebo-controlled crossover trial of the α2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis.
    Herrick AL; Murray AK; Ruck A; Rouru J; Moore TL; Whiteside J; Hakulinen P; Wigley F; Snapir A
    Rheumatology (Oxford); 2014 May; 53(5):948-52. PubMed ID: 24489014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].
    Correa MJ; Mariz HA; Andrade LE; Kayser C
    Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon.
    Friedman EA; Harris PA; Wood AJ; Stein CM; Kurnik D
    Clin Pharmacol Ther; 2007 Apr; 81(4):503-9. PubMed ID: 17301734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Mavrikakis ME; Lekakis JP; Papamichael CM; Stamatelopoulos KS; Kostopoulos ChC; Stamatelopoulos SF
    Int J Vitam Nutr Res; 2003 Feb; 73(1):3-7. PubMed ID: 12690904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
    DiGiacomo RA; Kremer JM; Shah DM
    Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders.
    Maricq HR; Weinrich MC; Valter I; Palesch YY; Maricq JG
    J Rheumatol; 1996 Dec; 23(12):2068-78. PubMed ID: 8970043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud's Phenomenon.
    Wilkinson JD; Leggett SA; Marjanovic EJ; Moore TL; Allen J; Anderson ME; Britton J; Buch MH; Del Galdo F; Denton CP; Dinsdale G; Griffiths B; Hall F; Howell K; MacDonald A; McHugh NJ; Manning JB; Pauling JD; Roberts C; Shipley JA; Herrick AL; Murray AK
    Arthritis Rheumatol; 2018 Jun; 70(6):903-911. PubMed ID: 29457381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon: effects of oral L-arginine supplementation.
    Khan F; Belch JJ
    J Rheumatol; 1999 Nov; 26(11):2389-94. PubMed ID: 10555898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome.
    Mohrland JS; Porter JM; Smith EA; Belch J; Simms MH
    Ann Rheum Dis; 1985 Nov; 44(11):754-60. PubMed ID: 3904643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cold-induced cutaneous vasoconstriction is mediated by Rho kinase in vivo in human skin.
    Thompson-Torgerson CS; Holowatz LA; Flavahan NA; Kenney WL
    Am J Physiol Heart Circ Physiol; 2007 Apr; 292(4):H1700-5. PubMed ID: 17172270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
    Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
    J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.
    Schiopu E; Hsu VM; Impens AJ; Rothman JA; McCloskey DA; Wilson JE; Phillips K; Seibold JR
    J Rheumatol; 2009 Oct; 36(10):2264-8. PubMed ID: 19755613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of vascular reactivity in scleroderma: new insights into Raynaud's phenomenon.
    Flavahan NA
    Rheum Dis Clin North Am; 2008 Feb; 34(1):81-7; vii. PubMed ID: 18329534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.